Latest news

  • 27 March 2019

    Sensorion reports its 2018 annual results. 75% of patients enrolled in the Sens-111 clinical trial. Read

  • 11 March 2019

    Sensorion strengthens its financial structure by issuing a €4.7 million nominal bond issue subscribed by new European investors and management. Bpifrance has selected Sensorion for its program "Hub Health Tech". Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more